PDE10A and Parkinson disease: Given the importance of striatal dopamine signaling for disorders such as schizophrenia, Parkinson’s disease, L-DOPA-induced dyskinesia and others, PDEs (including PDE10A) have been investigated as potential targets for pharmaceutical interventions in these disorders (e.g., [3,4,5]).